Superbugs are spreading as India faces gaps in drug supply, access to treatment
While antibiotics are being overused in some places, leading to the rise of deadly superbugs, in other parts of the world, people are dying because they can't access these life-saving drugs at all.A study, published in The Lancet Infectious Diseases, was led by the Global Antibiotic Research and Development Partnership (GARDP), a non-profit that works to improve access to antibiotics, looked at nearly 1.5 million cases of infections caused by carbapenem-resistant Gram-negative (CRGN) bacteria across eight low- and middle-income countries, including India, Brazil, and South Africa.advertisementCRGN bacteria are dangerous because they are resistant to "last-line" antibiotics. These are medicines that are used when all others fail.
Yet, the study found that only 6.9% of patients in these countries received the right treatment.INDIA CARRIES THE HEAVIEST BURDENIndia had the largest number of cases among all countries studied. It also procured 80% of the full antibiotic courses examined. But despite this, only 7.8% of people with CRGN infections received the proper treatment.This points to a gap between drug supply and actual access to treatment.A full course of antibiotics means the complete number of doses a patient must take to fully fight off an infection.
The study found that only 6.9% of patients in 8 countries, including India, received the right treatment. ()
advertisementMissing out on even a part of this treatment makes it less effective and more dangerous in the long run.These drug-resistant bacteria are commonly found in water, food, the environment, and even in our own bodies. They can cause serious infections like urinary tract infections (UTIs), pneumonia, and food poisoning.Newborn babies, elderly people, and hospital patients are especially at risk, particularly those in intensive care units (ICUs).CRGN infections are tough to treat because the bacteria no longer responds to some of the most powerful antibiotics we have. This is where the crisis deepens: in places where these infections are rising, the drugs needed to treat them are either missing or too expensive.THE ACCESS CRISISFor years, the focus has been on the overuse of antibiotics.According to Dr. Jennifer Cohn, GARDP's Global Access Director, the reality is that many people in low- and middle-income countries with deadly drug-resistant infections are "dying because they can't get the antibiotics they need," she was quoted by BBC.The study looked at eight different intravenous antibiotics that are active against these resistant bacteria.
Bacterial infections are tough to treat because the bacteriano longer responds to some of the most powerful antibiotics we have. ()
Tigecycline, one of the drugs in the study, was the most widely used. But even then, only about 1 lakh full courses were available across all eight countries, far fewer than the 1.5 million people who needed them.WHY ARE PATIENTS MISSING OUT?As per the study, there are many reasons why patients don't receive the right treatment.This could be because they aren't reaching the right hospital or clinic, not getting an accurate diagnosis, not able to access the correct antibiotics or there's a high cost of newer drugs.Many of these antibiotics are simply too expensive for the average patient in countries like India. Without better policies, price regulation, and access programs, millions will continue to suffer or die needlessly.SMARTER POLICIESThe experts said that two things are needed urgently: stronger rules to prevent misuse of antibiotics and better systems to make them affordable and available to those who truly need them.But access alone isn't enough. The world is also facing a shrinking pipeline of new antibiotics.advertisementWith fewer companies investing in antibiotic research, the options for treating future infections are limited.India has one of the highest burdens of antimicrobial resistance (AMR) in the world. But researchers say the country also holds great potential to lead the global fight against drug-resistant infections.
India has one of the highest burdens of antimicrobial resistance (AMR) in the world. ()
India's strong pharmaceutical sector is already leading efforts in antibiotic innovation. From developing new drugs to improving diagnostics, the country has a head start.Experts suggest that India can further improve by gathering local data. This would help identify what's needed, where the gaps are, and how to fix them. Some states are already trying new models.For instance, Kerala is using a "hub-and-spoke" system where smaller clinics get support from larger hospitals in treating complex infections.Another solution is pooled procurement, where hospitals or states buy drugs together in bulk, reducing costs. This has worked for cancer medicines and could be tried for antibiotics too.In the end, the battle against superbugs is not just about using antibiotics wisely, it's also about making sure they're within everyone's reach.Trending Reel
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
3 days ago
- Time of India
Rare group blood secured for complicated delivery
Rourkela: In a remarkable display of co-ordination, a unit of the rare Bombay Phenotype Rh-negative blood group was transported from Mumbai to Rourkela for a pregnant woman facing delivery complications. Tired of too many ads? go ad free now The blood, crucial for the caesarean operation of Khusbun Nisha (30) was delivered to a private hospital in Rourkela on Friday. Khusbun Nisha, a resident of Barbil in Keonjhar district, was admitted to the hospital five days ago. Doctors determined that a caesarean section was necessary due to her placenta previa condition. However, the operation required a unit of Bombay Phenotype Rh-negative blood, one of the rarest blood types globally. The private hospital initially requested the blood from the Rourkela Government Hospital's blood component separation unit. Upon discovering the unavailability of the rare blood type locally, the patient's family reached out to Dr. M Soren, the unit's in-charge, for assistance. Dr. Soren contacted the Universal Blood Cell in Mumbai, which managed to secure the blood by Wednesday night. A green corridor was established to expedite the blood transportation. On Thursday, the blood was flown from Mumbai to Ranchi. Volunteers, co-ordinated by Rourkela social worker Anupam Gupta, collected the blood at Ranchi airport, repacked it in ice, and sent it via the Bokaro-Allepy Express train to Rourkela, arriving at 7:30 pm. Upon arrival, Gupta handed over the blood to Dr. Soren, who confirmed its compatibility with the patient's sample. The blood was then delivered to the private hospital on Friday, ready for use during the caesarean operation. Tired of too many ads? go ad free now "This blood group is the rarest of the rare, and after significant efforts, we managed to secure a unit from Mumbai. It has been sent to the private hospital for the patient's use," said Dr. M Soren. Sources indicate that only 8 to 10 persons in India possess the Bombay Phenotype Rh-negative blood group.
Time of India
4 days ago
- Time of India
'Very unusual': 68-year-old woman with new blood type found; compatible only with herself
. Scientists have discovered a new blood type in a 68-year-old woman from the French overseas region of Guadeloupe. The blood group has been named 'Gwada Negative' and is only found in one woman across the globe. Thierry Peyrard, a medical biologist at the EFS, said, "She is the only person in the world who is compatible with herself', as reported by AFP. Peyrard explained that the woman got her blood type from both her parents, as each of them carried the mutated gene. He said that such an instance was 'very unusual'. The research team that made this discovery announced their findings in a presentation at the International Society of Blood Transfusion's Congress in Milan, which concluded on June 4. The research team had initially met the woman in Paris in 2011 when she was undergoing routine checkups before a surgery, when doctors could not ascertain her blood group, reported the French blood establishment (EFS). At the time, research methods were not advanced enough to solve the case, which remained unsolved for eight years. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Una madre soltera que conducía un Ferrari rojo casi acaba en la cárcel. Más información Undo In 2019, researchers used high-throughput gene sequencing , a method that allows faster and deeper DNA analysis, to re-examine the woman's blood. Over the next two years, they carefully studied her full genetic makeup. The woman's strange lab test results ultimately led to the discovery of a mutation in a gene called PIGZ, which changes the way proteins anchor to the surface of blood cells, as reported by LiveScience. Till now, EFS has recognised 47 blood group systems. The ABO blood group systems which was initially identified by Austrian-American biologist Dr Karl Landsteiner, is the first and the most familiar blood group system. DNA sequencing in the latest years has accelerated the discovery of new blood groups in the recent years. Blood group systems play a crucial role in safe blood transfusions, as the body rejects antigens that it perceives as foreign. The most common ABO blood typing system describes whether people have both the antigens of 'A', 'B', one of them or neither of them. In the ABO system, individuals with both A and B antigens (AB blood type) can recieve blood from any blood group as their body recognises both the antigens. On the other hand, people with O blood type can only receive blood from other O-type donors as they do not have A or B antigens. Peryard and his colleagues are now aiming to find other people with the same blood group as "Discovering new blood types means offering patients with rare blood a better level of care," said the EFS statement.
Hans India
22-06-2025
- Hans India
Imported seafood increasing resistance to colistin, a potent antibiotic: Study
A team of US researchers on Sunday said it has identified a way that colistin (a potent, last-resort antibiotic) resistance genes are spreading via imported seafood. Colistin is used only to treat people with dangerous, life-threatening bacterial infections that have developed resistance to other drugs. But it's not foolproof. Worldwide, resistance to colistin is spreading, further diminishing treatment options and putting infected people at higher risk. Researchers from the University of Georgia recently identified a way that colistin resistance genes are spreading. In a new study, microbiologist Issmat Kassem, and his group have reported the first isolation of colistin-resistance genes in bacteria found in imported shrimp and scallops, purchased from 8 food markets around Atlanta. 'Many people don't know that most seafood consumed in the U.S. is imported, Kassem said, including about 90 per cent of shrimp. Imported seafood is screened for contaminants but the process doesn't catch everything, especially antimicrobial resistance genes. 'The bacteria that were carrying colistin resistance genes are not normally screened.' Kassem and his group also found that some of the resistance genes are carried on plasmids — round bits of genetic material that can be transmitted from bacteria to bacteria. Antimicrobial resistant infections kill hundreds of thousands of people globally every year, and antimicrobial resistance is a rising public health menace. Colistin was first introduced in the 1950s to treat infections by pathogenic Gram-negative bacteria, but it takes a heavy toll on patients, including increased risk of damage to the nerves and kidneys. It was discontinued in the U.S. in the 1980s. However, Kassem noted, other countries continued to use it in agricultural settings, both to treat infections and to promote animal growth. Colistin was eventually reintroduced to human medicine because it was one of the few options available to treat certain bacterial infections. The World Health Organization categorises colistin as a high priority critically important antibiotic, which means it is an essential option for treating serious human infections. Researchers cautioned that the group identified 1 source of colistin resistance, but there could be other, and they're likely spreading.
